JCR Pharmaceuticals Co Ltd 2024 Annual Report
The report describes JCR's J-Brain Cargo® technology as opening treatment possibilities for rare diseases, with JR-141 approved in Japan and further clinical development underway globally. It highlights more than 17 pipeline products in lysosomal storage disorders and the expansion of the technology into gene therapy. The report also presents sustainability governance through advisory, sustainability and environmental committees.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Annual Report
Pages: 12
Back to company
JCR Pharmaceuticals Co Ltd
Jcr Report
The report describes JCR's J-Brain Cargo® technology as opening treatment possibilities for rare diseases, with JR-141 approved in Japan and further clinical development underway globally. It highlights more than 17 pipeline products in lysosomal storage disorders and the expansion of the technology into gene therapy. The report also presents sustainability governance through advisory, sustainability and environmental committees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Annual Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees